Nuvectis Pharma, Inc. NVCT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $4.11M-19.3% | $5.09M-11.9% | $5.77M+59.8% | $3.61M-1.8% | $3.68M-18.1% | ||
| $2.15M-14.9% | $2.53M+25.3% | $2.02M-32.3% | $2.98M+57.9% | $1.89M-3.3% | ||
| -$6.26M+17.8% | -$7.62M+2.3% | -$7.79M-18.2% | -$6.6M-18.4% | -$5.57M+13.7% | ||
| -$6.05M+17.3% | -$7.31M+2.0% | -$7.46M-17.8% | -$6.33M-18.8% | -$5.33M+14.7% | ||
| -$0.26+16.1% | -$0.31+29.5% | -$0.44-46.7% | -$0.30-11.1% | -$0.27+25.0% | ||
| -$0.26+16.1% | -$0.31+29.5% | -$0.44-46.7% | -$0.30-11.1% | -$0.27+25.0% | ||
| 23.4M+7.3% | 21.8M-4.0% | 22.7M+6.3% | 21.4M+7.2% | 19.9M+16.5% | ||
| 23.4M+7.3% | 21.8M-4.0% | 22.7M+6.3% | 21.4M+7.2% | 19.9M+16.5% | ||
| $210K-30.7% | $303K-8.7% | $332K+27.2% | $261K+10.6% | $236K+17.4% | ||
| -$6.26M+17.8% | -$7.62M+2.3% | -$7.79M-18.2% | -$6.6M-18.4% | -$5.57M+13.7% | ||
| -$6.26M+17.8% | -$7.62M+2.3% | -$7.79M-18.2% | -$6.6M-18.4% | -$5.57M+13.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Nuvectis Pharma, Inc. profitable?
- Nuvectis Pharma, Inc. is not currently profitable: it reported a net loss of $27.2M over the trailing twelve months.
- What is Nuvectis Pharma, Inc.'s earnings per share?
- Nuvectis Pharma, Inc.'s diluted EPS over the trailing twelve months is $-1.31.
- Where does Nuvectis Pharma, Inc.'s income statement data come from?
- Every line is extracted from Nuvectis Pharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.